Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Saved in:
| Title: | Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. |
|---|---|
| Authors: | Trapani D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Jin Q; Data Science, Dana-Farber Cancer Institute, Boston, MA., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Rugo HS; University of California at San Francisco, San Francisco, CA., Reeder-Hayes KE; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC., Traina T; Memorial Sloan Kettering Cancer Center, New York, NY., Abdou Y; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC., Falkson C; University of Alabama, Birmingham, AL., Abramson V; Vanderbilt University, Nashville, TN., Ligibel J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Chen W; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Come S; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA., Nohria A; Harvard Medical School, Boston, MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA., Ryabin N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Tayob N; Harvard Medical School, Boston, MA; Data Science, Dana-Farber Cancer Institute, Boston, MA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Mayer EL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: erica_mayer@dfci.harvard.edu. |
| Source: | Clinical breast cancer [Clin Breast Cancer] 2025 Jun; Vol. 25 (4), pp. e419-e430.e5. Date of Electronic Publication: 2024 Dec 31. |
| Publication Type: | Comparative Study; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39890560 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Trapani+D%22">Trapani D</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Jin+Q%22">Jin Q</searchLink>; Data Science, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Miller+KD%22">Miller KD</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; University of California at San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Reeder-Hayes+KE%22">Reeder-Hayes KE</searchLink>; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Traina+T%22">Traina T</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Abdou+Y%22">Abdou Y</searchLink>; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Falkson+C%22">Falkson C</searchLink>; University of Alabama, Birmingham, AL.<br /><searchLink fieldCode="AU" term="%22Abramson+V%22">Abramson V</searchLink>; Vanderbilt University, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Ligibel+J%22">Ligibel J</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Chen+W%22">Chen W</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Come+S%22">Come S</searchLink>; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Nohria+A%22">Nohria A</searchLink>; Harvard Medical School, Boston, MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ryabin+N%22">Ryabin N</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Tayob+N%22">Tayob N</searchLink>; Harvard Medical School, Boston, MA; Data Science, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Burstein+HJ%22">Burstein HJ</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Mayer+EL%22">Mayer EL</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: erica&#95;mayer@dfci.harvard.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100898731%22">Clinical breast cancer</searchLink> [Clin Breast Cancer] 2025 Jun; Vol. 25 (4), pp. e419-e430.e5. <i>Date of Electronic Publication: </i>2024 Dec 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Comparative Study; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100898731 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0666 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215268209%22">15268209 </searchLink><i>NLM ISO Abbreviation: </i>Clin Breast Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39890560 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clbc.2024.12.018 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e419 Titles: – TitleFull: Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Trapani D – PersonEntity: Name: NameFull: Jin Q – PersonEntity: Name: NameFull: Miller KD – PersonEntity: Name: NameFull: Rugo HS – PersonEntity: Name: NameFull: Reeder-Hayes KE – PersonEntity: Name: NameFull: Traina T – PersonEntity: Name: NameFull: Abdou Y – PersonEntity: Name: NameFull: Falkson C – PersonEntity: Name: NameFull: Abramson V – PersonEntity: Name: NameFull: Ligibel J – PersonEntity: Name: NameFull: Chen W – PersonEntity: Name: NameFull: Come S – PersonEntity: Name: NameFull: Nohria A – PersonEntity: Name: NameFull: Ryabin N – PersonEntity: Name: NameFull: Tayob N – PersonEntity: Name: NameFull: Tolaney SM – PersonEntity: Name: NameFull: Burstein HJ – PersonEntity: Name: NameFull: Mayer EL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2025 Jun Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1938-0666 Numbering: – Type: volume Value: 25 – Type: issue Value: 4 Titles: – TitleFull: Clinical breast cancer Type: main |
| ResultId | 1 |
